Home Johnson & Johnson rises despite warning on pandemic costs
Economic News, Investments, News, Stocks

Johnson & Johnson rises despite warning on pandemic costs

Johnson & Johnson (NYSE: JNJ) is among a select group of 16 companies actively working on a vaccine for coronavirus, rushing to be the first with a cure as it battles rivals such as Pfizer, Gilead Sciences, and GlaxoSmithKline.

The US medical and consumer goods group said earlier this month only a few days ago it was teaming up with the Beth Israel Deaconess Medical Center to speed up its vaccine development, which is currently at the preclinical testing stage. The firm, which is traded on the New York Stock Exchange, added that it should be able to identify a potential vaccine from its various prospects by the end of the month.

The New Jersey-based group, led by chief executive Alex Gorsky (pictured), has set up a timetable for human clinical trials allowing for a potential vaccine on November 2020, even though hitting that deadline, to cure the most widespread virus of this century, depends on many variables.

Johnson & Johnson stocks are up almost 5% in morning trading, even though the stock accumulated a 20% loss year-to-date. Today’s gains are in line with the overall market trend, mostly driven by positive sentiment towards the impact of the $2trn stimulus package to battle a slowdown brought about by the pandemic that Congress should pass on soon.

The business employs more than 130,000 people worldwide, serving more than 1 billion patients through its medical equipment and pharmaceutical solutions, and the company is scheduled to release its full-year earnings guidance for 2020 on April 14.

Johnson & Johnson chief financial officer, Joseph Wolk, said this week it will be an impossible task to predict how sales are going to look like this year, considering the widespread disruptive nature of the coronavirus outbreak.  He said: “One thing I know for certain is we’re going to be 100 per cent precisely wrong”.

Trusted & Regulated Stock & CFD Brokers

Rating

What we like

  • 0% Fees on Stocks
  • 5000+ Stocks, ETFs and other Markets
  • Accepts Paypal Deposits

Min Deposit

$200

Charge per Trade

Zero Commission on real stocks

Rating

64 traders signed up today

Visit Now

67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Available Assets

  • Total Number of Stocks & Shares5000+
  • US Stocks
  • German Stocks
  • UK Stocks
  • European
  • ETF Stocks
  • IPO
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 Zero Commission
  • NASDAQ Zero Commission
  • DAX Zero Commission
  • Facebook Zero Commission
  • Alphabet Zero Commission
  • Tesla Zero Commission
  • Apple Zero Commission
  • Microsoft Zero Commission

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account
  • Paypall
  • Skrill
  • Neteller

Rating

What we like

  • Sign up today and get $5 free
  • Fractals Available
  • Paypal Available

Min Deposit

$0

Charge per Trade

$1 to $9 PCM

Rating

Visit Now

Investing in financial markets carries risk, you have the potential to lose your total investment.

Available Assets

  • Total Number of Shares999
  • US Stocks
  • German Stocks
  • UK Stocks
  • European Stocks
  • EFTs
  • IPOs
  • Funds
  • Bonds
  • Options
  • Futures
  • CFDs
  • Crypto

Charge per Trade

  • FTSE 100 $1 - $9 per month
  • NASDAQ $1 - $9 per month
  • DAX $1 - $9 per month
  • Facebook $1 - $9 per month
  • Alphabet $1 - $9 per month
  • Telsa $1 - $9 per month
  • Apple $1 - $9 per month
  • Microsoft $1 - $9 per month

Deposit Method

  • Wire Transfer
  • Credit Cards
  • Bank Account

Alejandro Arrieche

Alejandro Arrieche

Alejandro is a financial writer with 7 years of experience in financial management and financial analysis. He writes technical content about economics, finance, investments, and real estate and have also assisted financial businesses in building their digital marketing strategy. His favorite topics are value investing and financial analysis.